Smurf2 Suppresses Proliferation and Cell Cycle of Triple‐Negative Breast Cancer Cells by Promoting the Polyubiquitination and Degradation of RPL35A
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Siyu Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Ubiquitin-Protein Ligases, Ubiquitination, Ribosomal Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Key Research and Development Plan of Xuzhou, National Natural Science Foundation of China, Postgraduate Research & Practice Innovation Program of Jiangsu Province.
Abstract (Originalsprache)
Human L35a ribosomal protein (RPL35A) has been reported to confer higher drug resistance and viability to triple‐negative breast cancer (TNBC) cells, but the mechanism related to its promotion of TNBC malignant progression is still unclear. Here, we found that silencing of RPL35A could inhibit the proliferation of TNBC cells by suppressing the G1/S phase transition. Furthermore, SMAD‐specific E3 ubiquitin protein ligase 2 (Smurf2) was found to be a potential upstream ubiquitin ligase of RPL35A. Smurf2 could interact with RPL35A and promote its degradation and K63‐linked polyubiquitination, thereby suppressing the G1/S phase transition and proliferation of TNBC cells. In addition, the roles of Smurf2 were confirmed in a xenograft mouse model. Finally, we found a negative correlation between the protein levels of RPL35A and Smurf2 in human TNBC tissues. In summary, Smurf2 inhibits the proliferation of TNBC cells by blocking the cell cycle process, which is associated with regulating RPL35A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Institute of Digestive Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Research Center of Digestive Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Zhiyi Liu
Förderung
- The Key Research and Development Plan of Xuzhou
- National Natural Science Foundation of China
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- Jiangsu Provincial Medical Key Discipline
- Chinese Young Breast Experts Research Project
- Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan
Zitieren
APA
Wei, S., Liu, Y., Wang, Z., Wei, T., Zhou, W., Li, W., Zhang, J., Liu, Z., & Liu, Z. (2025). Smurf2 Suppresses Proliferation and Cell Cycle of Triple‐Negative Breast Cancer Cells by Promoting the Polyubiquitination and Degradation of RPL35A. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70394
Vancouver
Wei S, Liu Y, Wang Z, Wei T, Zhou W, Li W, et al. Smurf2 Suppresses Proliferation and Cell Cycle of Triple‐Negative Breast Cancer Cells by Promoting the Polyubiquitination and Degradation of RPL35A. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70394
BibTeX
@article{Wei2025,
author = {Wei, Siyu and Liu, Yuying and Wang, Zhihao and Wei, Ti and Zhou, Wenkai and Li, Wanwan and Zhang, Jiaxin and Liu, Zhiyi and Liu, Zhao},
title = {Smurf2 Suppresses Proliferation and Cell Cycle of Triple‐Negative Breast Cancer Cells by Promoting the Polyubiquitination and Degradation of RPL35A},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70394}
}
EUVIMED